Pfizer (PFE) stock in focus as Priovant, a partnership between the company and Roivant Sciences (ROIV) posts positive trial ...

If a monthly high dose can drive higher weight loss with a side effect profile that keeps patients on the medication, "Pfizer ...

Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its ...

The stock price of BridgeBio plunged 15% Thursday as Pfizer's reported decision to withdraw a Vyndamax patent in the European Union triggered fears of earlier generic entry in the blockbuster ...

As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North ...

New weight loss drug by Pfizer shows promising results in trial - Pfizer acquired the drug’s developer following a bidding ...

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

The U.S. FDA has accepted and granted Priority Review for Pfizer’s supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...

Biopharma’s obsession with the weight loss sector—projected to exceed $130 billion in revenue by 2035—shows no signs of ...

Looking ahead, we believe key programs in our R&D portfolio offer significant opportunities to help address substantial patient needs and drive Pfizer's growth in the coming years. I will mention some ...